| Clinical Disorder | N | Comparative Data | Proportion with Night Sweats (if Comparison Group) or Proportion in Whom Night Sweats Resolved with Treatment | |
|---|---|---|---|---|
| Autoimmune | POEMS syndrome | 1 | No | Disorder treated, night sweats resolved59 |
| Rheumatoid arthritis | 1 | No | Disorder treated, night sweats resolved60 | |
| Giant cell arteritis | 1 | No | Disorder treated, night sweats resolved61 | |
| Cardiovascular | Aortic dissection, chronic | 1 | No | Disorder treated, night sweats resolved62 |
| Nocturnal/Prinzmetal angina | 1 | No | Disorder treated, night sweats persisted63 | |
| Endocrine | Diabetes insipidus | 1 | No | Disorder treated/night sweats resolved64 |
| Hyperthyroidism | 1 | No | Disorder treated, night sweats resolved65 | |
| GI | GERD | 12 | No | Disorder treated, night sweats resolved (100%)57 |
| Infectious disease | HIV | |||
| P24 Ag+, HIV− | 3816 | Yes | 5/58 (9%) | |
| P24 Ag−, HIV− | 38/3758 (1%)66 | |||
| HIV-negative | 328 | Yes | 20/328 (6%) night sweats | |
| Acute HIV+ | 59/328 (18%) | |||
| Chronic HIV+ | 39/328 (12%)67 | |||
| HIV seroconverters | 110 | Yes | 18/22 (82%) night sweats | |
| Nonseroconverters | 6/88 (7%)68 | |||
| IV drug users, HIV+ | 223 | Yes | 33/124 (27%) night sweats | |
| IV drug users, HIV− | 13/99 (13%)69 | |||
| Hodgkin disease, HIV+ | 16 | Yes | 2/5 (40%) night sweats | |
| Hodgkin disease, HIV− | 3/11 (27%)70 | |||
| HIV+ with persistent generalized lymphadenopathy | 88 | Yes | 12/38 (32%) night sweats | |
| HIV+ with lymphoma | 7/50 (14%)71 | |||
| TB patients, HIV+ | 158 | Yes | 24/48 (50%) | |
| TB patients, HIV− | 11/31 (35%)72 | |||
| HIV patients, TB+ | 899 | Yes | 15/44 (34%) night sweats | |
| 108/855 (14%)73 | ||||
| HIV patients, TB− | 31 | No | 27/31 (87%) 4.8 episodes per week pretreatment; 1.6 episodes/week posttreatment74 | |
| HIV+, MAC | 25 | No | 21/25 (84%) had night sweats pretreatment; | |
| post treatment one of 25 (4%) had night sweats75 | ||||
| 24 | No | 18/24 (75%) had night sweats pretreatment; | ||
| posttreatment 6/24 (25%) had night sweats76 | ||||
| 187 | No | 67/187 (36%) had night sweats pretreatment; | ||
| posttreatment 40% had fewer night sweats when treated with 4 drugs; | ||||
| 1748 | Yes | 70% had fewer when treated with 3 drugs77 | ||
| HIV+, TB+ | 88/267 (33%) had HIV+ with TB+ | |||
| HIV+, TB− | 191/1471 (13%) had HIV+ without TB | |||
| HIV+, TB+ | 128/267 (48%) had night sweats past 24 hours | |||
| HIV+, TB− | 368/1471 (25%)78 had night sweats past month | |||
| Viral URI/Mononucleosis | 356 | Yes | Cohort matched on age, sex, date of diagnosis; night sweats more common in mononucleosis (P = .000001)79 | |
| Tuberculosis | ||||
| Hospitalized patients awaiting TB diagnosis (44 were TB-positive) | 101 | Yes | No significant difference in rate of night sweats between those with TB and those without TB80 | |
| Hospitalized patients in isolation awaiting diagnosis | 563 | Yes | 26/47 (55%) of TB patients reported night sweats; 141/516 (27%) of non-TB patients reported night sweats52,81 | |
| Emergency department patients with sputum tested for TB | 145 | Yes | 13/28 (46%) with positive sputum reported night sweats; 29/113 (26%) with negative sputum reported night sweats51 | |
| Hospitalized patients awaiting TB diagnosis | 101 | Yes | 44/100 were TB-positive; no association between reported night sweats and TB positivity80 | |
| Cysticercosis (Coenurus) | 1 | No | Case history; night sweats and lymphoma-like symptoms ceased with excision of larval cysts82 | |
| Medications | Antidepressants | |||
| Sertraline | 1 | No | Case history; night sweats resolved with discontinuation of sertraline suggest night sweats may be sign of “serotonin syndrome”83 | |
| Venlafaxine | 1 | Case history; night sweats resolved when drug was discontinued84 | ||
| Efavirenz | 1 | No | Case history; night sweats resolved with discontinuation of drug85 | |
| Neoplastic and hematologic | Hemangioma, hepatic | 1 | No | Night sweats resolved when hemangioma removed86 |
| Lymphoma | 85 | No | 4/14 (29%) with EBV Hodgkin disease had night sweats; in 75%, night sweats improved after treatment of disease87 | |
| Lymphadenopathy | 258 | Yes | 14/85 (17%) patients with TB had night sweats | |
| 24/98 (25%) patients with lymphoma had night sweats | ||||
| 5/17 (29%) patients with metastatic cancer had night sweats | ||||
| 0/6 (0%) of patients with sarcoidosis had night sweats | ||||
| 5.36 (14%) of patients with nonspecific reactive hyperplasia had night sweats88 | ||||
| Myelofibrosis | 24 | No | 21/24 (88%) night sweats improved >50% with JAK1 and JAK2 inhibitor treatment89 | |
| Prostate cancer, inflammatory | 1 | No | Case study; treated, night sweats resolved90 | |
| Psychiatric/behavioral | Depression | |||
| HIV+ and depressed | 62 | Yes | 16/28 (57%) had night sweats | |
| HIV+ and not depressed | 7/34 (21%)91 | |||
| Night terrors | 1 | No | Case study, night sweats resolved with treatment for posttraumatic syndrome92 | |
| Panic disorder | 175 | No | 26/175 (15%) of attacks occurred at night; | |
| Sleep disturbance | 46/175 (26%) associated with sweating93 | |||
| Obstructive sleep apnea | ||||
| Snoring/daytime sleepiness | 4680 | Yes | 14/202 (14%) with snoring/sleepiness; | |
| No snoring/sleepiness | 179/4478 (4%) with no snoring/sleepiness58 | |||
| Apnea–hypopnea index ≥15 | 282 | Yes | Subjective night sweats in 28/114 (25%) | |
| Apnea–hypopnea index <15 | Subjective night sweats in 50/167 (30%)38 |
GI, gastrointestinal; GERD, gastroesophageal reflux disease; IV, intravenous; TB, tuberculosis; URI, upper respiratory infection; EBV, Epstein-Barr virus; MAC, Mycobacterium avium complex.